Wave Life Sciences (NASDAQ: WVE) posts positive early WVE-006 AATD study data

Rhea-AI Filing Summary

Wave Life Sciences reported that its drug candidate WVE-006 showed positive data in the ongoing Phase 1b/2a RestorAATion-2 study for alpha-1 antitrypsin deficiency (AATD). This is an early- to mid‑stage clinical trial, so positive results can be an important step toward later-stage development if they are confirmed over time.

The company also scheduled an investor conference call at 8:30 a.m. ET on September 3, 2025, to discuss the results and plans to share an investor slide presentation on its website. Most of the information in the related press release is being treated as supplemental disclosure rather than as part of its formal financial reporting.

Insights

Biotech and clinical development analyst

Wave reports encouraging early WVE-006 data in AATD, details pending.

Wave Life Sciences disclosed positive data from its ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency. Phase 1b/2a trials are designed to assess safety and early signals of activity, so favorable results can support advancing a program but do not yet establish clinical benefit. The announcement indicates progress for a key clinical asset targeting a defined genetic liver and lung disease population.

The company is dedicating an investor call and slide deck on September 3, 2025, underscoring the perceived importance of these results to its pipeline story. However, the excerpt does not provide quantitative efficacy or safety data, so it is not possible to gauge the magnitude of benefit or any risk signals. Future disclosures in company materials will need to outline the detailed dataset, trial design, and next-step plans to understand how this may influence development timelines and the overall investment case.

false 0001631574 0001631574 2025-09-03 2025-09-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 3, 2025

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore		001-37627		98-1356880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7 Straits View #12-00, Marina One
East Tower
Singapore		018936
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
$0 Par Value Ordinary Shares		WVE		The Nasdaq Global Market

Item 7.01 Regulation FD Disclosure.

On September 3, 2025, Wave Life Sciences Ltd. (the “Company” or “Wave”) issued a press release announcing positive data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006, the Company’s clinical candidate for alpha-1antitrypsin deficiency (AATD). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The press release also indicated that Wave management will host an investor conference call at 8:30 a.m. ET on September 3, 2025, to discuss the results. For purposes of the call, and in connection with the announcement described above, the Company plans to share an investor slide presentation during the investor conference call, which will be available on the “Investors” section of the Company’s website at https://ir.wavelifesciences.com/.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

The information set forth in the press release referred to in Item 7.01 above, other than the third and eleventh paragraphs thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 7.01 is furnished and not filed:

Exhibit No.		Description
99.1		Press Release issued by Wave Life Sciences Ltd. dated September 3, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.
By:		/s/ Paul B. Bolno, M.D.
		Paul B. Bolno, M.D.
		President and Chief Executive Officer

Date: September 3, 2025

FAQ

What did Wave Life Sciences (WVE) announce regarding WVE-006?

Wave Life Sciences announced positive data from its ongoing Phase 1b/2a RestorAATion-2 study of WVE-006, its clinical candidate for treating alpha-1 antitrypsin deficiency (AATD).

What disease is Wave Life Sciences targeting with WVE-006?

WVE-006 is being developed for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can affect the lungs and liver due to low or dysfunctional alpha-1 antitrypsin protein.

What stage of clinical development is WVE-006 in for Wave Life Sciences (WVE)?

WVE-006 is in an ongoing Phase 1b/2a clinical trial called RestorAATion-2, an early- to mid-stage study focused on safety and initial signs of activity in patients.

Is Wave Life Sciences holding an investor call about the WVE-006 data?

Yes. Wave Life Sciences scheduled an investor conference call at 8:30 a.m. ET on September 3, 2025, to discuss the WVE-006 study results and will share an investor slide presentation on its investor relations website.

Where can investors find more details on Wave Life Sciences (WVE) WVE-006 results?

More details are in a press release attached as Exhibit 99.1 and in an investor slide presentation available on the company’s investor relations website at https://ir.wavelifesciences.com/.

Does the WVE-006 disclosure affect Wave Life Sciences formal financial statements?

Most of the information about the WVE-006 data and presentation is being furnished rather than filed, meaning it is supplemental to the companys formal financial reporting obligations.